INKT

Investor Moves

Name	Value	Action	Change	Price	Last Price
Jim SimonsRenaissance Technologies $-116.0K ExitQ1 2026 $116k -- $10.66
Jim SimonsRenaissance Technologies $-88.4K TrimQ4 2025 $88k -- $10.66

Insider Trades

Name	Value	Action	Price	Last Price
Ryan BarbaraDirector $13k1k shares SellJun 4, 2026 $12.80 $10.66
Ryan BarbaraDirector $6.3k500 shares SellJun 4, 2026 $12.68 $10.66
Ryan BarbaraDirector $4.6k300 shares SellMar 10, 2026 $15.28 $10.66
Ryan BarbaraDirector $2k200 shares SellMar 9, 2026 $10.17 $10.66
Ryan BarbaraDirector $7.8k500 shares SellMar 10, 2026 $15.57 $10.66
Ryan BarbaraDirector $7.7k500 shares SellMar 10, 2026 $15.30 $10.66

News

globenewswire.comMiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meetingglobenewswire.comJun 3

globenewswire.comMiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illnessglobenewswire.comMay 28

globenewswire.comMiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communicationsglobenewswire.comMay 20

seekingalpha.comMiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 15

marketbeat.comMiNK Therapeutics Q1 Earnings Call Highlightsmarketbeat.comMay 15

Trade INKT

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.

CEO: Jennifer S. Buell
IPO Date: Oct 15, 2021

Market Data

Open: $12.35
High: $12.45
Low: $11.86
Volume: 13.7K
Avg Volume: 49.2K
52W High: $76.00
52W Low: $6.80

Valuation

Market Cap: $60.5M
Enterprise Value: $51M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$5.9M
Revenue: $0
Net Income: -$12.5M
Cash: $13.4M
Debt: $5.2M

Events

EarningsAug 13

EPS est. -0.6